- Helius Medical Technologies (HSM) has appointed Frederick Fantazzia as Vice President of Sales & Marketing, North America
- Fantazzia will help drive the commercialization of the company’s Portable Neuromodulation Stimulator (PoNS) treatment in the United States
- The PoNS is a non-surgical device that acts as a short-term treatment of the symptoms of multiple sclerosis
- Helius Medical Technologies is a neurotech company focused on neurological wellness
- Helius Medical Technologies Inc. (HSM) is up 0.61 per cent on the day, trading at $16.55 per share
Helius Medical Technologies (HSM) has appointed Frederick Fantazzia as Vice President of Sales & Marketing, North America.
Prior to joining Helius, Mr. Fantazzia worked for LivaNova, a global medical technology company that designs, develops, manufactures, and sells innovative therapeutic solutions, from 2016 until 2021.
At LivaNova, Mr. Fantazzia also served as VP of North American sales and marketing for that company’s commercialization of a technology for the treatment of epilepsy.
Dane Andreeff, Helius’ interim president and CEO, commented on the appointment.
“Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption,” he said.
Mr. Fantazzia will help drive the commercialization of the company’s Portable Neuromodulation Stimulator (PoNS) treatment in the United States.
The PoNS is an innovative non-surgical device that delivers electrical stimulation to the surface of the tongue as a short-term treatment of the symptoms of multiple sclerosis.
“I believe Helius is a rising star in the development of innovative neuromodulation technologies to treat conditions related to the effects of neurological disease and trauma,” said Mr. Fantazzia. “With the company’s PoNS device now authorized for sale in the U.S., I am excited to join the team at this important inflection point.”
Helius Medical Technologies is a neurotech company focused on neurological wellness.
The company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself.
Helius Medical Technologies Inc. (HSM) is up 0.61 per cent on the day, trading at $16.55 per share as of 1:02 pm ET.